Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 13 Jan 2020
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
Stephen Padilla, 6 days ago
The Lancet Commission on Hypertension Group has recently released a position statement that contains a list of recommendations for the improvement of accuracy standards for devices that measure blood pressure (BP).

Bloodstream infections common among epidermal necrolysis patients

23 Jul 2019
Despite sepsis being UK’s top avoidable disease, many hospitals still fail to administer intravenous antibiotics to patients within the hour, adding to the staggering death toll rates.

Bloodstream infections (BSIs) are common among patients with epidermal necrolysis (EN) and are mostly caused by Staphylococcus aureus and Pseudomonas aeruginosa, a recent study has found. Skin cultures may help predict such infections.

Researchers performed a retrospective, single-centre observational study of 98 patients (median age, 49.6 years; 56 percent female) who had acute-phase EN with body surface area (BSA) involvement 10 percent. Information about blood and skin cultures, as well as the time and severity of BSI were collected and included in the analysis.

Almost half (46.9 percent; n=46) experienced at least one BSI episode after a median of 7 days after admission. A total of 85 cases were reported, and the incidence rate was 33.3 BSIs per 1,000 days of hospitalization per patient. More than half (52.2 percent; n=24) of the BSI patients experienced septic shock, while 26 percent (n=12) died.

S. aureus and P. aeruginosa accounted for majority of the positive blood cultures, each detected in 36.9 percent of the samples. Almost a fourth (23.9 percent) of blood cultures were polymicrobial.

Similarly, S. aureus (38 percent) was the most common infectious agent during the first skin culture, while P. aeruginosa (79 percent) dominated the third skin cultures. In 71.1 percent of the cases, bacteria isolated from the skin cultures corresponded with the bacteria responsible for the BSI.

In terms of diagnostic performance, skin cultures of S. aureus had a sensitivity of 88.2 percent and a specificity of 60.7 percent. Cultures of P. aeruginosa, on the other hand, had corresponding values of 75.0 percent and 58.4 percent.

Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 13 Jan 2020
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
Stephen Padilla, 6 days ago
The Lancet Commission on Hypertension Group has recently released a position statement that contains a list of recommendations for the improvement of accuracy standards for devices that measure blood pressure (BP).